{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"96.8","upperLimit":"99.9","value":"99.5"},{"groupId":"OG001","lowerLimit":"88.3","upperLimit":"95.3","value":"92.6"}]}],"title":"OS rate at 2 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.1","upperLimit":"96.5","value":"94.1"},{"groupId":"OG001","lowerLimit":"80.6","upperLimit":"89.8","value":"85.9"}]}],"title":"OS rate at 3 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.3","upperLimit":"89.2","value":"85.0"},{"groupId":"OG001","lowerLimit":"66.0","upperLimit":"78.1","value":"72.6"}]}],"title":"OS rate at 5 years (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken once daily","id":"OG000","title":"AZD9291 80mg Tablet"},{"description":"Taken once daily","id":"OG001","title":"Placebo Tablet"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS) stage IIA-IIIA patients","reportingStatus":"POSTED","timeFrame":"Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.","title":"Overall Survival Rate at 2, 3 and 5 Years","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}